Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Parkinsonism Relat Disord ; 35: 36-41, 2017 02.
Article in English | MEDLINE | ID: mdl-27890451

ABSTRACT

OBJECTIVE: To determine the diagnostic utility of olfactory testing in patients with neurodegenerative parkinsonism. METHODS: The Sniffin' Sticks test battery for assessment of odor identification, discrimination, and threshold was applied to patients with Parkinson's disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) as well as healthy controls (HC). Two different cohorts were analyzed: A PD/healthy control that included PD patients and HC as well as a PD/diseased control cohort for which patients PD, MSA and PSP were recruited. The former cohort was exploited to calculate cut-off values that discriminate PD patients from HC with a sensitivity (sensitivity-weighted cut-off) or specificity (specificity-weighted cut-off) exceeding 95%, respectively. The PD/diseased controls cohort was used to determine the diagnostic accuracy using these cut-off values in discriminating patients with neurodegenerative parkinsonism. RESULTS: PD patients (n = 67) performed significantly worse in olfactory testing than HC (n = 41) and patients with MSA (n = 23) or PSP (n = 23). There was no significant difference in olfactory function between MSA and PSP patients. Diagnostic performance of the identification subscore was similar to the sum score of the Sniffin' Sticks test (AUC identification test 0.94, AUC sum score 0.96), while threshold and discrimination subscores were inferior. In patients with parkinsonism, the specificity-weighted cut-off predicted a diagnosis of PD with a sensitivity and specificity of 76.6 and 87.0%, respectively. The discriminative value of this cut-off in separating PD from MSA was 76.7% (sensitivity) and 95.7% (specificity). The corresponding, prevalence-adjusted positive predictive value of olfactory testing exceeded 95%. CONCLUSIONS: Our data suggest that assessment of olfactory function, particularly odor identification, can be useful to discriminate PD from atypical parkinsonian disorders, particularly MSA patients.


Subject(s)
Odorants , Parkinsonian Disorders/diagnosis , Parkinsonian Disorders/physiopathology , Smell/physiology , Aged , Cohort Studies , Cross-Sectional Studies , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/physiopathology
4.
Nervenarzt ; 86(2): 167-73, 2015 Feb.
Article in German | MEDLINE | ID: mdl-25659843

ABSTRACT

BACKGROUND: The assessment of health-related quality of life (hrQoL) is an important tool in therapy studies and in the treatment of patients with Huntington's disease (HD). In the absence of causal interventions, HD therapy targets the alleviation of symptoms aiming to improve impaired hrQoL. The aim of this study was to determine the impact of disease characteristics on hrQoL in HD. METHODS: A total of 80 genetically confirmed HD patients underwent an assessment using the Unified Huntington's Disease Rating Scale, the Beck Depression Inventory, the Hamilton Rating Scale and the SF-36, a scale for the assessment of physical and mental QoL. RESULTS: Multiple regression analysis revealed that health-related physical and mental QoL was considerably influenced by the functional capacity. The mental QoL also correlated with the degree of depressive symptoms, age and the number of CAG repeats. However, there was no statistical relation between QoL and motor and cognitive abilities. DISCUSSION: This study underlines the relationship between function capacity and depressive symptoms with mental and physical QoL. This is the first time that hrQoL has been investigated in a German speaking cohort. The results are in accordance with previous studies of hrQoL in HD.


Subject(s)
Depression/psychology , Huntington Disease/diagnosis , Huntington Disease/psychology , Mental Disorders/psychology , Movement Disorders/psychology , Quality of Life/psychology , Adult , Age Distribution , Aged, 80 and over , Cohort Studies , Comorbidity , Depression/diagnosis , Germany/epidemiology , Health Status Indicators , Humans , Huntington Disease/epidemiology , Mental Disorders/diagnosis , Middle Aged , Movement Disorders/diagnosis , Prognosis , Risk Assessment , Sex Distribution
6.
Eur J Neurol ; 20(6): 981-5, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23530751

ABSTRACT

BACKGROUND AND PURPOSE: Little is known about the natural history of non-traumatic compressive mononeuropathies. To improve patient management, prognostic factors and outcome in patients with non-traumatic peroneal and radial mononeuropathies were studied. METHODS: Retrospective clinical, electrophysiological and sonographic data of patients with non-traumatic peroneal and radial mononeuropathies were evaluated. Clinical, electrophysiological and sonographic evaluations had to take place 2-12 weeks after symptom onset and follow-up had to be for >6 months. RESULTS: Twenty-five patients with peroneal mononeuropathy and 58 with radial mononeuropathy were included. Mean follow-up was 8.9 ± 2.4 months. Approximately 90% of patients recovered to a muscle strength of British Medical Research Council grade 4 or 5. Multiple logistic regression analysis revealed conduction block on nerve conduction studies, younger age and less severe initial weakness as indicators for a good prognosis. Peripheral nerve ultrasound was not prognostic in the 40 patients where it was available. CONCLUSIONS: The present study shows a good prognosis for spontaneous recovery after non-traumatic acute-onset compressive peroneal and radial mononeuropathies. Patients with denervation on needle electromyography, older age and severe initial weakness have a poorer prognosis and should be closely monitored to facilitate timely surgery whenever weakness persists. Peripheral nerve ultrasound seems to be of limited prognostic value in these mononeuropathies.


Subject(s)
Peroneal Neuropathies/diagnosis , Peroneal Neuropathies/epidemiology , Radial Neuropathy/diagnosis , Radial Neuropathy/epidemiology , Radiculopathy/diagnosis , Radiculopathy/epidemiology , Acute Disease , Adult , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Mononeuropathies/diagnosis , Mononeuropathies/epidemiology , Prognosis , Retrospective Studies
7.
Eur J Neurol ; 20(1): 16-34, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23279440

ABSTRACT

BACKGROUND: A Task Force was convened by the EFNS/MDS-ES Scientist Panel on Parkinson's disease (PD) and other movement disorders to systemically review relevant publications on the diagnosis of PD. METHODS: Following the EFNS instruction for the preparation of neurological diagnostic guidelines, recommendation levels have been generated for diagnostic criteria and investigations. RESULTS: For the clinical diagnosis, we recommend the use of the Queen Square Brain Bank criteria (Level B). Genetic testing for specific mutations is recommended on an individual basis (Level B), taking into account specific features (i.e. family history and age of onset). We recommend olfactory testing to differentiate PD from other parkinsonian disorders including recessive forms (Level A). Screening for pre-motor PD with olfactory testing requires additional tests due to limited specificity. Drug challenge tests are not recommended for the diagnosis in de novo parkinsonian patients. There is an insufficient evidence to support their role in the differential diagnosis between PD and other parkinsonian syndromes. We recommend an assessment of cognition and a screening for REM sleep behaviour disorder, psychotic manifestations and severe depression in the initial evaluation of suspected PD cases (Level A). Transcranial sonography is recommended for the differentiation of PD from atypical and secondary parkinsonian disorders (Level A), for the early diagnosis of PD and in the detection of subjects at risk for PD (Level A), although the technique is so far not universally used and requires some expertise. Because specificity of TCS for the development of PD is limited, TCS should be used in conjunction with other screening tests. Conventional magnetic resonance imaging and diffusion-weighted imaging at 1.5 T are recommended as neuroimaging tools that can support a diagnosis of multiple system atrophy (MSA) or progressive supranuclear palsy versus PD on the basis of regional atrophy and signal change as well as diffusivity patterns (Level A). DaTscan SPECT is registered in Europe and the United States for the differential diagnosis between degenerative parkinsonisms and essential tremor (Level A). More specifically, DaTscan is indicated in the presence of significant diagnostic uncertainty such as parkinsonism associated with neuroleptic exposure and atypical tremor manifestations such as isolated unilateral postural tremor. Studies of [(123) I]MIBG/SPECT cardiac uptake may be used to identify patients with PD versus controls and MSA patients (Level A). All other SPECT imaging studies do not fulfil registration standards and cannot be recommended for routine clinical use. At the moment, no conclusion can be drawn as to diagnostic efficacy of autonomic function tests, neurophysiological tests and positron emission tomography imaging in PD. CONCLUSIONS: The diagnosis of PD is still largely based on the correct identification of its clinical features. Selected investigations (genetic, olfactory, and neuroimaging studies) have an ancillary role in confirming the diagnosis, and some of them could be possibly used in the near future to identify subjects in a pre-symptomatic phase of the disease.


Subject(s)
Guidelines as Topic , Parkinson Disease/diagnosis , Autonomic Nervous System Diseases/diagnosis , Autonomic Nervous System Diseases/etiology , Brain/pathology , Cognition Disorders/diagnosis , Cognition Disorders/etiology , Databases, Factual/statistics & numerical data , Diagnostic Imaging , Europe , Genetic Testing , Humans , Neurophysiology , Neuropsychological Tests , Olfaction Disorders/diagnosis , Olfaction Disorders/etiology , Parkinson Disease/complications , Risk Factors , Sleep Wake Disorders/diagnosis , Sleep Wake Disorders/etiology
8.
Eur J Neurol ; 20(1): 102-8, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22852790

ABSTRACT

BACKGROUND AND PURPOSE: Screening batteries to narrow down a target-at-risk population are essential for trials testing neuroprotective compounds aiming to delay or prevent onset of Parkinson's disease (PD). METHODS: The PRIPS study focuses on early detection of incident PD in 1847 at baseline PD-free subjects, and assessed age, male gender, positive family history, hyposmia, subtle motor impairment and enlarged substantia nigra hyperechogenicity (SN+). RESULTS: After 3 years follow-up 11 subjects had developed PD. In this analysis of the secondary outcome parameters, sensitivity and specificity of baseline markers for incident PD were calculated in 1352 subjects with complete datasets (10 PD patients). The best approach for prediction of incident PD comprised three steps: (i) prescreening for age, (ii) primary screening for positive family history and/or hyposmia, and (iii) secondary screening for SN+. CONCLUSION: With this approach, one out of 16 positively screened participants developed PD compared to one out of 135 in the original cohort. This corresponds to a sensitivity of 80.0%, a specificity of 90.6% and a positive predictive value of 6.1%. These values are higher than for any single screening instrument but still too low for a feasible and cost-effective screening strategy which might require longer follow-up intervals and application of additional instruments.


Subject(s)
Mass Screening/methods , Parkinson Disease/diagnosis , Parkinson Disease/epidemiology , Aged , Aged, 80 and over , Female , Humans , Longitudinal Studies , Male , Middle Aged , Parkinson Disease/pathology , Predictive Value of Tests , Substantia Nigra/pathology
9.
Fortschr Neurol Psychiatr ; 80(9): 492-500, 2012 Sep.
Article in German | MEDLINE | ID: mdl-22457226

ABSTRACT

The term "atypical Parkinson syndromes" usually encompasses the following diseases: multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). The differential diagnosis is still a challenge even for a movement disorders specialist, not least because of the distinct therapeutic approaches and disease prognosis. The aim of this review is to provide an overview of current diagnostic criteria and therapeutic approaches and to cite recent findings from clinical and experimental studies.


Subject(s)
Parkinsonian Disorders/diagnosis , Parkinsonian Disorders/therapy , Basal Ganglia Diseases/diagnosis , Basal Ganglia Diseases/therapy , Diagnosis, Differential , Humans , Magnetic Resonance Imaging , Multiple System Atrophy/diagnosis , Multiple System Atrophy/therapy , Prognosis , Supranuclear Palsy, Progressive/diagnosis , Supranuclear Palsy, Progressive/therapy
10.
J Neurol ; 257(Suppl 2): S268-75, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21080188

ABSTRACT

After more than 40 years of clinical use, levodopa (LD) still remains the gold standard for symptomatic efficacy in Parkinson's disease (PD). However, long-term treatment with LD is often complicated by the development of various types of motor response oscillations as well as drug-induced dyskinesias. These treatment-related motor complications evolve in approximately one-third of patients after only 2 years of LD exposure and, once established, they are difficult to treat and significantly contribute to overall disability and disease burden. Although first described soon after the introduction of LD, the pathophysiology of motor complications is still not completely understood. In fact, it is most likely that non-physiological pulsatile stimulation of dopamine receptors, which is followed by various downstream alterations, plays a key role in the development of LD-induced motor response oscillations and dyskinesias. This review outlines the various types of motor complications and will also address underlying mechanisms, treatment options, as well as impact on clinical disability and quality of life (QoL).


Subject(s)
Antiparkinson Agents/adverse effects , Dyskinesia, Drug-Induced/diagnosis , Levodopa/adverse effects , Parkinson Disease/drug therapy , Dyskinesia, Drug-Induced/physiopathology , Humans , Parkinson Disease/diagnosis , Parkinson Disease/physiopathology
11.
Nervenarzt ; 81(10): 1168-79, 2010 Oct.
Article in German | MEDLINE | ID: mdl-20857276

ABSTRACT

The differential diagnosis of parkinsonian syndromes is considered one of the most challenging in clinical neurology. Despite published consensus operational criteria for the diagnosis of Parkinson's disease (PD) and the various atypical parkinsonian disorders (APD), such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD), the clinical separation of APDs from PD carries a high rate of misdiagnosis. However, the early differentiation between APD and PD, each characterized by a very different natural history, is crucial for determining the prognosis and choosing a treatment strategy. Despite limitations the various modern magnetic resonance imaging (MRI) techniques have undoubtedly added to the differential diagnosis of neurodegenerative parkinsonism. In clinical practice conventional MRI with visual assessment of T2 and T1-weighted imaging is a well established method for the exclusion of symptomatic parkinsonism due to other pathologies and may also point to the diagnosis of APD. Furthermore, advances in MRI techniques, such as diffusion-weighted imaging (DWI), have enabled abnormalities in the basal ganglia and infratentorial brain structures in APD to be quantitatively illustrated.


Subject(s)
Brain/pathology , Diffusion Magnetic Resonance Imaging , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Parkinson Disease/diagnosis , Parkinsonian Disorders/diagnosis , Basal Ganglia/pathology , Basal Ganglia Diseases/diagnosis , Cerebral Cortex/pathology , Diagnosis, Differential , Humans , Multiple System Atrophy/diagnosis , Neurodegenerative Diseases/diagnosis , Parkinson Disease, Secondary/diagnosis , Supranuclear Palsy, Progressive/diagnosis
13.
Neuropsychologia ; 47(8-9): 1901-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19428422

ABSTRACT

In the present study we investigate decision making under ambiguity and decision making under risk in Parkinson's disease (PD) patients without cognitive impairment and in patients affected by Parkinson's disease dementia (PDD). In decisions under ambiguity, participants are not aware of the rules for gains and losses and have to learn about the utility of their selections through feedback. The two patient groups showed significant deficits and did not differ in the frequency of advantageous choices, though they had a markedly different cognitive profile. In decisions under risk, explicit information on the options' probabilities as well as on the associated gains and losses is given. PD patients and healthy controls performed at the same level, whereas PDD patients made significantly more risky and disadvantageous decisions. Results of the study suggest that both patient groups are impaired in decision making when learning by feedback and emotional processing is required, while only the PDD group shows difficulties when decision making is based on cognitive reasoning strategies.


Subject(s)
Decision Making/physiology , Parkinson Disease/physiopathology , Risk-Taking , Uncertainty , Aged , Analysis of Variance , Female , Germ Cells , Humans , Male , Middle Aged , Neuropsychological Tests , Probability , Statistics as Topic
14.
Epilepsy Res ; 86(1): 42-7, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19464851

ABSTRACT

PURPOSE: Patients undergoing long-term treatment with valproic acid (VPA) are prone to develop different features of the metabolic syndrome (MS). The aim of the present study was to evaluate the occurrence of non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and a pro-atherogenic lipid profile in patients undergoing VPA, carbamazepine (CBZ) and lamotrigine (LTG) monotherapy compared to healthy controls. METHODS: Abdominal ultrasound as well as measurement of serum fasting insulin and glucose, serum lipids and liver function parameters were performed in VPA (n=23), CBZ (n=22) and LTG (n=23) treated non-diabetic and non-obese epileptic patients compared to healthy controls (n=16). RESULTS: Ultrasound measurement demonstrated characteristics of fatty liver disease in 60.9% of VPA, in 22.7% of CBZ, in 8.7% of LTG treated patients and in 12.5% of the healthy controls, with highest level of steatosis seen in VPA treated patients. In addition, patients on VPA monotherapy showed a higher body-mass index (BMI) when compared to LTG treated patients and controls (p

Subject(s)
Anticonvulsants/adverse effects , Fatty Liver/blood , Fatty Liver/chemically induced , Insulin Resistance/physiology , Lipids/blood , Abdomen/diagnostic imaging , Adult , Anticonvulsants/pharmacology , Anticonvulsants/therapeutic use , Blood Glucose/drug effects , Body Mass Index , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Epilepsy, Generalized/drug therapy , Fatty Liver/physiopathology , Female , Humans , Liver Function Tests , Male , Ultrasonography/methods , Young Adult
15.
Eur J Radiol ; 71(2): 269-74, 2009 Aug.
Article in English | MEDLINE | ID: mdl-18534801

ABSTRACT

PURPOSE: This study describes several cases of endovascular coil embolization of the proximal internal mammary artery injured by blind approach to the subclavian vein for central venous catheter or pacemaker lead insertion. MATERIALS AND METHODS: We conducted a retrospective analysis of five patients with iatrogenic arterial lesions of the internal mammary artery (IMA). The lesions occurred in three patients from a puncture of the subclavian vein during insertion of a central venous catheter and in two patients from a puncture of the subclavian vein for insertion of a pacemaker lead. Four patients had acute symptoms of bleeding with mediastinal hematoma and hematothorax and one patient was investigated in a chronic stage. A pseudoaneurysm was detected in all five patients. All four acute and hemodynamic unstable patients required hemodynamic support. RESULTS: In all patients, embolization was performed using a coaxial catheter technique, and a long segment of the IMA adjacent distally and proximally to the source of bleeding was occluded with pushable microcoils. In one patient, additional mechanically detachable microcoils were used at the very proximal part of the IMA. Microcoil embolization of the IMA was successful in all patients, and the source of bleeding was eliminated in all patients. CONCLUSION: Transarterial coil embolization is a feasible and efficient method in treating acute bleeding and pseudoaneurysm of the IMA and should be considered if mediastinal hematoma or hemathorax occurs after blind puncture of the subclavian vein.


Subject(s)
Aneurysm, False/etiology , Aneurysm, False/therapy , Catheterization, Central Venous/adverse effects , Electrodes, Implanted/adverse effects , Embolization, Therapeutic/methods , Mammary Arteries/injuries , Wounds, Penetrating/etiology , Wounds, Penetrating/therapy , Adult , Aged , Female , Humans , Male , Middle Aged , Pacemaker, Artificial/adverse effects , Treatment Outcome , Young Adult
16.
Cephalalgia ; 29(2): 179-87, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18823362

ABSTRACT

The aim of the current study was to estimate the prevalence of all primary headaches and cranial neuralgias in the general community. As part of the population-based Bruneck Study, 574 men and women aged 55-94 years underwent extensive neurological and laboratory examinations involving a standardized headache interview. In the Bruneck Study population the lifetime prevalence of all primary headaches combined and of cranial neuralgias was 51.7 and 1.6%, respectively. Tension-type headache (40.9%) and migraine (19.3%) emerged as the most common types of headache. In men and women aged 55-94 years the 1-year prevalence of primary headaches was high at 40.5%. In this age range headaches caused significant impairment of health-related quality of life. The Bruneck Study has confirmed the high lifetime prevalence of primary headaches and cranial neuralgias in the general population and provided first valid prevalence data for all primary headaches based on International Classification of Headache Disorders, 2nd edition criteria.


Subject(s)
Cranial Nerves , Headache Disorders, Primary/epidemiology , Neuralgia/epidemiology , Aged , Aged, 80 and over , Female , Humans , Interviews as Topic , Italy/epidemiology , Logistic Models , Longitudinal Studies , Male , Middle Aged , Prevalence , Quality of Life
17.
Neurology ; 71(9): 670-6, 2008 Aug 26.
Article in English | MEDLINE | ID: mdl-18725592

ABSTRACT

BACKGROUND: A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here. METHODS: Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology. RESULTS: The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS alpha-synuclein-positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality. CONCLUSIONS: These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.


Subject(s)
Autonomic Nervous System Diseases/diagnosis , Brain/pathology , Cerebellar Ataxia/diagnosis , Multiple System Atrophy/diagnosis , Parkinsonian Disorders/diagnosis , Autonomic Nervous System Diseases/physiopathology , Basal Ganglia/pathology , Basal Ganglia/physiopathology , Brain/physiopathology , Cerebellar Ataxia/physiopathology , Cerebellum/pathology , Cerebellum/physiopathology , Diagnosis, Differential , Inclusion Bodies/metabolism , Inclusion Bodies/pathology , Multiple System Atrophy/physiopathology , Parkinsonian Disorders/physiopathology , alpha-Synuclein/metabolism
18.
Eur J Neurol ; 14(1): 66-72, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17222116

ABSTRACT

To assess severity and progression of self-perceived dysautonomia and their impact on health-related quality of life (Hr-QoL) in multiple system atrophy (MSA), twenty-seven patients were recruited by the European MSA Study Group (EMSA-SG). At baseline, all patients completed the Composite Autonomic Symptom Scale (COMPASS) and the 36 item Short Form Health Survey (SF-36), and they were assessed using the 3-point global disease severity scale (SS-3) and the Unified MSA Rating Scale (UMSARS). After 6 months follow-up, the self completed COMPASS Change Scale (CCS), the SF-36, SS-3, and UMSARS were obtained. MSA patients showed marked self-perceived dysautonomia at baseline visit and pronounced worsening of dysautonomia severity on the CCS at follow-up. Severity and progression of dysautonomia did not correlate with age, disease duration, motor impairment and overall disease severity at baseline. There were no significant differences between genders and motor subtypes. Baseline COMPASS scores were, however, inversely correlated with SF-36 scores. Progression of self-perceived dysautonomia did not correlate with global disease progression. Hr-QoL scores were stable during follow-up. This is the first study to investigate self-perceived dysautonomia severity in MSA and its evolution over time. Our data suggest that dysautonomia should be recognized as a key target for therapeutic intervention in MSA.


Subject(s)
Autonomic Nervous System Diseases/physiopathology , Multiple System Atrophy/physiopathology , Self Concept , Aged , Aged, 80 and over , Autonomic Nervous System Diseases/epidemiology , Disease Progression , Female , Follow-Up Studies , Health Surveys , Humans , Male , Middle Aged , Multiple System Atrophy/epidemiology , Prospective Studies
19.
J Neural Transm (Vienna) ; 114(5): 585-8, 2007.
Article in English | MEDLINE | ID: mdl-17195917

ABSTRACT

To compare frequency and degree of orthostatic hypotension (OH) in Parkinson's disease (PD) and Parkinson's disease with dementia (PDD) and its effect on attention and word fluency, blood pressure (BP) and heart rate changes during tilt were determined in 10 PD and 8 PDD patients. Attention and word fluency were evaluated in supine and tilted position using standard neuropsychological tests. OH defined as systolic BP (SBP) drop of >/=20 mmHg and/or diastolic BP (DBP) drop of >/=10 mmHg was present in 5 PDD patients and in 2 PD patients. SBP drop was significantly greater in PDD than in PD patients (P < 0.05). Whereas word fluency was unaffected by tilt in both patient groups, attention as assessed with the Test of Everyday Attention (TEA) deteriorated significantly in the PDD group, correlating with blood pressure response (DeltaSBP and TEA-2, r = 0.828, P < 0.05; DeltaDBP and TEA-2, r = 0.828, P < 0.05). We conclude that OH is frequent in PDD and should be addressed therapeutically since it may exacerbate attentional dysfunction.


Subject(s)
Cognition Disorders/epidemiology , Dementia/epidemiology , Parkinson Disease/epidemiology , Shy-Drager Syndrome/epidemiology , Attention/physiology , Autonomic Nervous System Diseases/diagnosis , Autonomic Nervous System Diseases/physiopathology , Blood Pressure/physiology , Cognition Disorders/physiopathology , Comorbidity/trends , Dementia/physiopathology , Humans , Language Disorders/epidemiology , Language Disorders/physiopathology , Language Tests , Neuropsychological Tests , Parkinson Disease/physiopathology , Prevalence , Shy-Drager Syndrome/physiopathology
20.
Eur J Neurol ; 13(10): 1146-8, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16987170

ABSTRACT

We performed a placebo-controlled cross-over trial of riluzole (100 mg b.i.d.) in 10 patients with probable multiple system atrophy (MSA) administering riluzole and placebo for 4 weeks each with a 4-week washout period. Outcome measures evaluated short-term anti-Parkinsonian effects using the Unified Parkinson's Disease Rating Scale (UPDRS) subscales (UPDRS-II, activities of daily living; UPDRS-III, motor examination; sum of UPDRS-II and -III) before and at the end of each treatment phase. Delta values were calculated by subtracting the UPDRS scores measured at the end of each treatment arm from those before onset of each medication phase. Riluzole was generally well tolerated. There were no significant anti-Parkinsonian effects of riluzole comparing the UPDRS delta values for both treatment arms using the Wilcoxon signed-rank test. It is unlikely that riluzole treatment could have clinically meaningful anti-Parkinsonian effects in MSA. A trial assessing the disease-modifying potential of riluzole in MSA is underway.


Subject(s)
Multiple System Atrophy/drug therapy , Riluzole/therapeutic use , Aged , Cross-Over Studies , Female , Gastrointestinal Diseases/chemically induced , Humans , Male , Middle Aged , Multiple System Atrophy/complications , Multiple System Atrophy/epidemiology , Parkinson Disease/complications , Parkinson Disease/drug therapy , Placebo Effect , Riluzole/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...